Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

BACKGROUND: Preclinical studies have documented antitumor activity of PARP inhibition both in vitro and in vivo, against Ewing sarcoma cells. This study aimed to translate that observation into a clinical trial to assess the efficacy and tolerability of olaparib, a PARP inhibitor, in patients with a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Choy, Edwin, Butrynski, James E, Harmon, David C, Morgan, Jeffrey A, George, Suzanne, Wagner, Andrew J, D’Adamo, David, Cote, Gregory M, Flamand, Yael, Benes, Cyril H, Haber, Daniel A, Baselga, Jose M, Demetri, George D
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2014
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4230717/
https://ncbi.nlm.nih.gov/pubmed/25374341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-813
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia